Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
50 hedge funds and large institutions have $38.1M invested in Regulus Therapeutics in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 49 → 50 (+1)
0.02% less ownership
Funds ownership: 0.45% → 0.43% (-0.02%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
34% less capital invested
Capital invested by funds: $58.1M → $38.1M (-$20M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$361K |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$228K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$189K |
| 4 |
VF
Virtu Financial
New York
|
+$87.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$41.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.57M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$558K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$449K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$408K |
| 5 |
Millennium Management
New York
|
-$351K |
RGLS Hedge Fund Activity: Q1 2018 in Review
50 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2018, worth a combined $38.1M — down 34% from $58.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RGLS positions and 9 closed out — a net gain of 1 holder — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $361K. The largest seller was Broadfin Capital, exiting entirely with an estimated $1.57M sold.
- 50 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2018, up from 49 in Q4 2017.
- Funds reported $38.1M of Regulus Therapeutics stock for Q1 2018, down 34% quarter-over-quarter.
- 10 funds opened new Regulus Therapeutics positions in Q1 2018 and 9 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q1 2018 was Vanguard Group, an estimated $361K added.
- The largest Regulus Therapeutics seller in Q1 2018 was Broadfin Capital, an estimated $1.57M sold.
Based on aggregated 13F filings for Q1 2018.